Non-Alcoholic Steatohepatitis

Midwest CEPAC

Due to the COVID-19 pandemic, the NASH assessment will be paused now, and all additional deadlines and public comment opportunities will be pushed back approximately 2-3 months.


ICER plans to assess the comparative clinical effectiveness and value of obeticholic acid (Intercept) for the treatment of non-alcoholic steatohepatitis (NASH). Obeticholic acid has received a breakthrough therapy designation from the FDA, with an anticipated decision expected in the first half of 2020.

Date of Review: May 2020

For questions, please contact Ellie Adair, Deputy Chief Operating Officer, at eadair@icer-review.org.